The Trump administration has withdrawn a plan to ban menthol cigarettes in the U.S., in a setback to health regulators and activists. The Food and Drug Administration had in April 2022 proposed to ban the sale of menthol cigarettes and flavored cigars,
A proposed ban on menthol cigarettes and flavored cigars was withdrawn by the Trump administration, a blow to public health advocates who attribute thousands of premature deaths to the additive.Most Read from BloombergWhat Happened to Hanging Out on the Street?
Despite the seemingly restrictive nature of the FDA's proposed ruling, I remain highly optimistic about the resilience and adaptability
The Biden administration is floating a long-awaited proposal to make cigarettes less addictive by capping their nicotine levels
In the final days of President Joe Biden’s term, the US Food and Drug Administration (FDA) has placed a proposal that could make cigarettes less addictive and simpler to quit. The agency says it will drastically reduce the amount of nicotine levels in cigarettes,
The Food and Drug Administration authorized the marketing of 20 Zyn nicotine pouch products through the premarket tobacco product application
The proposed rule from the Food and Drug Administration comes in the final ... tobacco companies like Reynolds American and Altria are almost certain to challenge it in court, delaying implementation.
The Trump administrations removed FDA's plan to ban menthol cigarettes. The Biden administration did not finalize the rule amid opposition.
A government website shows the Trump administration has withdrawn the Food and Drug Administration’s proposed ban of menthol-flavored
A rather historic U.S. Food and Drug Administration (FDA) proposal aims to make cigarettes and other tobacco products far less addictive by reducing their nicotine content.
Federal health officials on Thursday backed the public health benefits of nicotine pouches, authorizing Philip Morris International’s Zyn to help adult smokers cut back or quit cigarettes.
CAMBRIDGE, Mass. - Biogen Inc. (NASDAQ:BIIB), a $20.8 billion biotechnology company with a robust 75.6% gross profit margin, has reached a pivotal phase as regulatory agencies in the United States and Europe are now reviewing a higher dose regimen of nusinersen,